- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT01527058
68Ga-BNOTA-PRGD2 PET/CT in Healthy Volunteers and Lung Cancer Patients (GRGDLC)
Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Diagnostic Performance of 68Ga-BNOTA-PRGD2 in Healthy Volunteers and Lung Cancer Patients
Descripción general del estudio
Descripción detallada
Integrin αⅤβ3 is an important member of this receptor family and expressed preferentially on various types of tumor cells and the activated endothelial cells of tumor angiogenesis, but not or very low on the quiescent vessel cells and other normal cells. Therefore, the integrin αⅤβ3 receptor is becoming a valuable target for diagnosis and response evaluation of malignant tumors.
The tri-peptide sequence of arginine-glycine-aspartic acid (RGD) can specifically bind to the integrin αⅤβ3 receptor. Accordingly, a variety of radiolabeled RGD-based peptides have been developed for non-invasive imaging of integrin αⅤβ3 expression via positron emission tomography (PET) or single photon emission computed tomography (SPECT). Among all the RGD radiotracers studied, two PET imaging agents, 18F-Galacto-RGD and 18F-AH111585, have been investigated in clinical trials, and the results demonstrated that both radiotracers allowed the specific imaging of various types of tumors, and the tumor uptake correlated well with the expression of integrin αⅤβ3. Recently, series of RGD dimeric peptides with PEG linkers have been studied. The new types of RGD peptides showed much higher in vitro integrin αⅤβ3-binding affinity than the single RGD tri-peptide sequence, and importantly, they exhibited significantly increased tumor uptake and improved in vivo kinetics in animal models. As a representative, 68Ga-BNOTA-PRGD2 could be easily prepared and exhibited excellent in vivo behaviors in animal models. No adverse reactions are observed in animal models to date.
For the further interests in clinical translation of 68Ga-BNOTA-PRGD2, a open-label dynamic whole-body PET/CT study was designed to investigate radiation dosimetry, plasma pharmacokinetics, biodistribution, safety and diagnostic performance of 68Ga-BNOTA-PRGD2 in healthy volunteers and lung cancer patients. A single dose of nearly 111 MBq 68Ga-BNOTA-PRGD2 ( ≤ 40 µg BNOTA-PRGD2) will be intravenously injected into healthy volunteers and lung cancer patients. Visual and semiquantitative method will be used to assess the PET/CT images. Changes of blood pressure, pulse, respiration, temperature, routine blood and urine tests, serum alanine aminotransferase, albumin, and creatinine, and any adverse events will be collected from the volunteers. Adverse events will also be observed in the patients.
Tipo de estudio
Inscripción (Anticipado)
Fase
- Fase temprana 1
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Beijing, Porcelana, 100730
- Reclutamiento
- Department of Nuclear Medicine, Peking Union Medical College Hopital
-
Investigador principal:
- Fang Li, MD
-
Contacto:
- Fang Li, MD
- Número de teléfono: 86-10-65295502
- Correo electrónico: lifang@pumch.cn
-
Sub-Investigador:
- Zhaohui Zhu, MD, PhD
-
Sub-Investigador:
- Hongli Jing, MD
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
Healthy volunteers:
- Males and females, ≥30 and ≤ 70 years old
Cancer patients:
- Males and females, ≥30 years old
- CT and/or 18F-FDG PET/CT diagnosis in suspicion of primary or recurrent lung cancer.
- The lung cancer will be histologically confirmed or results of histology will be available.
Exclusion Criteria:
- Females planning to bear a child recently or with childbearing potential
- Renal function: serum creatinine >3.0 mg/dL (270 μM/L)
- Liver function: any hepatic enzyme level more than 5 times upper limit of normal.
- Known severe allergy or hypersensitivity to IV radiographic contrast.
- Patients not able to enter the bore of the PET/CT scanner.
- Inability to lie still for the entire imaging time because of cough, pain, etc.
- Inability to complete the needed examinations due to severe claustrophobia, radiation phobia, etc.
- Concurrent severe and/or uncontrolled and/or unstable other medical disease that, in the opinion of the Investigator, may significantly interfere with study compliance.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Diagnóstico
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: 68Ga-BNOTA-PRGD2 PET/CT scanning
Determine if 68Ga-BNOTA-PRGD2 PET/CT is safe and effective method for imaging of lung cancer
|
Cancer patients, single intravenous bolus injection of nearly 111 MBq 68Ga-NOTA-PRGD2 on day one of the treatment period, dynamic whole-body PET/CT for determination of effective dose, kinetics of 68Ga-BNOTA-PRGD2 in blood, organs, and tumors Healthy volunteers, single intravenous bolus injection of nearly 111 MBq 68Ga-BNOTA-PRGD2 on day one of the treatment period, dynamic whole-body PET/CT for determination of effective dose, kinetics of 68Ga-BNOTA-PRGD2 in blood and organs
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Valoración visual y semicuantitativa de lesiones y biodistribución
Periodo de tiempo: Un año
|
El análisis visual se realizará mediante lectura consensuada por al menos 3 médicos con experiencia en medicina nuclear.
El análisis semicuantitativo lo realizará la misma persona para todos los casos, y se medirán los valores estandarizados de captación (SUV) de tumor y órganos.
|
Un año
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Blood pressure
Periodo de tiempo: One year
|
Blood pressure of healthy volunteers will be measured at three time points: right before injection, after scanning, and 24 hours after treatment.
|
One year
|
Pulse
Periodo de tiempo: One year
|
Pulse will be measured at three time points for each healthy volunteer: right before injection, after scanning, and 24 hours after treatment.
|
One year
|
Respiration frequency
Periodo de tiempo: One year
|
Respiration frequency will be measured at three time points for each healthy volunteer: right before injection, after scanning, and 24 hours after treatment.
|
One year
|
Temperature
Periodo de tiempo: One year
|
Temperature will be measured at three time points for each healthy volunteer: right before injection, after scanning, and 24 hours after treatment.
|
One year
|
Routine blood test
Periodo de tiempo: One year
|
Routine blood test of healthy volunteers will be measured at two time points: right before and 24 hours after treatment.
|
One year
|
Routine urine test
Periodo de tiempo: One year
|
Routine urine test of healthy volunteers will be measured at two time points: right before and 24 hours after treatment.
|
One year
|
Serum alanine aminotransferase
Periodo de tiempo: One year
|
Serum alanine aminotransferase of healthy volunteers will be measured at two time points: right before and 24 hours after treatment.
|
One year
|
Serum albumin
Periodo de tiempo: One year
|
Serum albumin of healthy volunteers will be measured at two time points: right before and 24 hours after treatment.
|
One year
|
Serum creatinine
Periodo de tiempo: One year
|
Serum creatinine of healthy volunteers will be measured at two time points: right before and 24 hours after treatment.
|
One year
|
Adverse events collection
Periodo de tiempo: One year
|
Adverse events within 5 days after the injection and scanning of healthy volunteers and patients will be followed and assessed.
|
One year
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Silla de estudio: Fang Li, MD, Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Anticipado)
Finalización del estudio (Anticipado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- PUMCHNM002
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Cáncer de pulmón
-
Abramson Cancer Center of the University of PennsylvaniaTerminadoPaciente con cancerEstados Unidos
-
Peking Union Medical College HospitalTerminadoEncuesta | Estado nutricional | Paciente con cancerPorcelana
-
Ankara Medipol UniversityReclutamientoCuidados personales | Inmunoterapia | Manejo de síntomas | Paciente con cancerPavo
-
Northwestern UniversityGenzyme, a Sanofi CompanyRetiradoCANCER DE PROSTATAEstados Unidos
-
Fundacao ChampalimaudTerminado
-
University College London HospitalsTerminado
-
GenSpera, Inc.RetiradoCancer de prostata.Estados Unidos
-
University of Colorado, DenverColorado State UniversityRetiradoRealidad virtual | Diagnóstico por imagen | Educación del paciente | Paciente con cancerEstados Unidos
-
Dana-Farber Cancer InstituteTerminadoCancer de RIÑON | Cancer de prostata | Cáncer genitourinarioEstados Unidos
-
Rabin Medical CenterReclutamiento
Ensayos clínicos sobre 68Ga-BNOTA-PRGD2
-
Peking Union Medical College HospitalDesconocidoFibrosis Pulmonar, No EspecificadaPorcelana
-
Peking Union Medical College HospitalDesconocidoEnfermedad de la arteria coronariaPorcelana
-
Peking Union Medical College HospitalBeijing Tiantan HospitalDesconocido
-
Peking Union Medical College HospitalDesconocidoArtritis ReumatoidePorcelana
-
Peking Union Medical College HospitalDesconocido
-
Wuxi No. 4 People's HospitalDesconocidoCarcinoma Broncogénico | Linfoma Maligno | Carcinoma de mama | Cáncer de cabeza y cuello | Neoplasias de Tejidos Blandos | TumoresPorcelana
-
Peking Union Medical College HospitalReclutamiento
-
Peking Union Medical College HospitalReclutamiento
-
PentixaPharm GmbHTerminadoLinfoma del SNCDinamarca, Francia
-
Yusuf MendaNational Cancer Institute (NCI); National Institutes of Health (NIH); Holden Comprehensive...Activo, no reclutandoTumores neuroendocrinosEstados Unidos